Oncology · Imaging AgentRegulatory Approvalregulatorymid-term

FDA Accepts NDA for ZYOGREEN by PROVEPHARM SAS

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/15/2026, 12:30:33 PM

Assessment confidence: 58% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the NDA for ZYOGREEN represents a significant regulatory milestone that could enhance PROVEPHARM SAS's competitive position in the oncology imaging market. Pharma strategy teams should evaluate the potential impact on existing products and market dynamics. Regulatory context from FDA (FDA AP — ZYOGREEN (ORIG)) supports the near-term read. Assessment grounded in 24 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of ZYOGREEN's approval on existing imaging agents and consider strategic positioning. The strongest clinical anchor is A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ClinicalTrials.gov), mechanism alignment (io ); sponsor/company relevance (astrazeneca). In Oncology · Imaging Agent, 4 regulatory and 5 competitive items passed relevance filtering for PROVEPHARM SAS.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer. This acceptance may position PROVEPHARM SAS favorably in the imaging agent market, potentially impacting competitors in oncology diagnostics.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ZYOGREEN (ORIG) (FDA). Entity match (provepharm sas); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The acceptance of the NDA indicates a positive regulatory trajectory for ZYOGREEN, but the final approval and market entry will depend on the outcomes of the FDA review process.

Key Risks

Elevated medium regulatory exposure for PROVEPHARM SAS could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval of ZYOGREEN could shift market share among imaging agents, influencing revenue streams for both PROVEPHARM SAS and its competitors in oncology diagnostics.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in adjuvant treatment for early-stage ER-positive breast cancer, a significant advancement in over 20 years.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in early-stage ER-positive breast cancer, impacting existing therapies.
Lead sponsor: BeOne Medicines. The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.
Portfolio teams should assess the implications of ZYOGREEN's approval on existing imaging agents and consider strategic positioning.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for FDA review outcomes and potential market entry strategies from PROVEPHARM SAS.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ZYOGREEN (ORIG)
FDAhigh relevance
Entity match (provepharm sas); Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — PADCEV (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
MHRA safety review gives UK plasma donations go ahead
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
ClinicalTrials.govhigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (AstraZeneca)
FDA document
View source
Management of Abdominal Post-surgical Scar With Ozoaqua Versus Standard Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Magnetic Resonance Imaging Assessment of Multiorgan Health in Obesity
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Characterization of Phenotypic and Genotypic Regressors for Imaging
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment

Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elranatamab: A novel B-cell maturation T-cell engager.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Repurposing licensed viral vaccines as anti-cancer therapeutics: Turning cold tumors hot.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

PROVEPHARM SAS
ZYOGREEN
oncology imaging agents
competitors in oncology diagnostics

Commercial impact

medium

The approval of ZYOGREEN could shift market share among imaging agents, influencing revenue streams for both PROVEPHARM SAS and its competitors in oncology diagnostics.

Regulatory impact

medium

The acceptance of the NDA indicates a positive regulatory trajectory for ZYOGREEN, but the final approval and market entry will depend on the outcomes of the FDA review process.

What to watch

Monitor the timeline for FDA review outcomes and potential market entry strategies from PROVEPHARM SAS.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.